-
DE
D63.0 – Anaemia in Neoplastic Disease Explained
D63.0 is the ICD-10 code for anaemia in neoplastic disease. It describes a reduction in red blood cells that occurs as a direct consequence of cancer and can significantly affect the quality of life of patients.
Add as Preferred SourceThings worth knowing about "D63.0"
D63.0 is the ICD-10 code for anaemia in neoplastic disease. It describes a reduction in red blood cells that occurs as a direct consequence of cancer and can significantly affect the quality of life of patients.
What is D63.0?
The ICD-10 code D63.0 stands for anaemia in neoplastic disease, referring to a reduction in red blood cells or haemoglobin that occurs as a consequence of a malignant tumour or cancer (neoplasm). It is not a standalone disease but a secondary condition frequently diagnosed in cancer patients. In clinical practice, this form of anaemia is classified as a secondary or tumour-associated anaemia.
Causes
Anaemia in neoplastic disease can arise through several different mechanisms:
- Tumour-related bleeding: Tumours can cause internal haemorrhage, leading to blood loss and a reduction in red blood cells.
- Bone marrow infiltration: When cancer cells invade the bone marrow, normal blood cell production (haematopoiesis) is disrupted.
- Inflammation-induced suppression: Cancer triggers chronic inflammatory responses that inhibit the production of red blood cells, a phenomenon known as anaemia of chronic disease.
- Nutritional deficiencies: Reduced food intake or malabsorption can lead to deficiencies in iron, vitamin B12, or folic acid.
- Chemotherapy and radiotherapy: Cancer treatments can damage the bone marrow and reduce erythrocyte (red blood cell) production.
- Haemolysis: In some cases, the tumour triggers accelerated destruction of red blood cells.
Symptoms
The symptoms of tumour-associated anaemia resemble those of other forms of anaemia but may be intensified by the underlying disease:
- Pronounced fatigue and exhaustion (cancer-related fatigue)
- Pallor of the skin and mucous membranes
- Shortness of breath, especially during physical activity
- Dizziness and headaches
- Rapid heartbeat (tachycardia)
- Difficulty concentrating
- Reduced physical capacity
Diagnosis
Diagnosis of anaemia in neoplastic disease typically involves the following investigations:
- Full blood count (haemogram): Measurement of haemoglobin (Hb), haematocrit, red blood cell count, and other parameters.
- Reticulocyte count: Assessment of the bone marrow capacity to produce new red blood cells.
- Iron metabolism markers: Serum ferritin, transferrin saturation, and soluble transferrin receptor levels.
- Vitamin B12 and folic acid: To rule out nutritional deficiency.
- Bone marrow biopsy: If infiltration by tumour cells is suspected.
- Imaging: To evaluate the primary tumour and potential metastases.
Treatment
Treatment is guided by the underlying cause of anaemia, the general health status of the patient, and the nature of the malignancy:
Nutritional Support and Supplementation
- Iron supplementation: Administered orally or intravenously, especially in cases of confirmed iron deficiency.
- Vitamin B12 and folic acid: Supplemented when a corresponding deficiency is identified.
Pharmacological Treatment
- Erythropoiesis-stimulating agents (ESAs): Substances such as epoetin alfa or darbepoetin alfa can stimulate red blood cell production. Their use is restricted to specific clinical situations (e.g., during chemotherapy) and must be carefully evaluated due to potential risks.
Blood Transfusion
- In cases of severe anaemia with haemoglobin levels below 7–8 g/dl, or in highly symptomatic patients, a blood transfusion may be required to rapidly raise haemoglobin levels.
Treatment of the Underlying Disease
- The most effective long-term strategy remains treating the underlying tumour through surgery, chemotherapy, radiotherapy, or immunotherapy.
Prognosis and Quality of Life
Anaemia in neoplastic disease is a frequent complication that significantly impacts the quality of life of cancer patients. Early detection and treatment can reduce fatigue, improve physical performance, and enhance the tolerability of cancer therapies. The overall prognosis depends primarily on the nature and stage of the underlying malignancy.
References
- Aapro, M. et al. (2018): Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines. Annals of Oncology, 29(Suppl 4), iv96–iv110.
- Ludwig, H. et al. (2013): Anaemia management in patients with haematological malignancies. Annals of Oncology, 24(11), 2840–2853.
- World Health Organization (WHO): International Statistical Classification of Diseases and Related Health Problems, 10th Revision (ICD-10), Code D63.0.
Building Blocks for a Healthy Life
As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.
Skip product gallery
Subscription available
Floral
For Healthy Oral Flora & Dental Care
Formulated lozenges with Dentalac®, lactic acid bacteria, and Lactoferrin CLN®30 lozenges
Regular price:
22,90 €
Discount
Subscription available
Lactoferrin 60 Capsules
For your universal protection
As one of the most valuable proteins in the body, lactoferrin is a natural component of the immune system.
60 Capsules
Sale price:
50,00 €
Regular price:
59,90 €
Subscription available
Multivitamin Mineral Complex
Daily basic supply: the complete spectrum of micronutrients
Natural multivitamin complex for the immune system, energy, and central body functions
30 Capsules
Regular price:
29,90 €
Subscription available
Natural Iron
For your iron balance
Specially formulated for your iron balance with plant-based curry leaf iron, Lactoferrin CLN®, and natural Vitamin C from rose hips.
30 Capsules
Regular price:
35,90 €